A Novel Antibody-Cell Conjugation Method to Enhance Cellular Therapies for the Treatment of Hematological Malignancies

作者
Matthew Joshua Frank,Andy Huang,Sai-Wen Tang,Robert S. Negrin,Sonny C. Hsiao,Everett H. Meyer
出处
期刊:Blood [Elsevier BV]
卷期号:130: 1532-1532 被引量:1
标识
DOI:10.1182/blood.v130.suppl_1.1532.1532
摘要

Abstract Introduction Cellular therapies including γδ T cells, NK-92 cells, and cytokine-induced killer (CIK) cells have shown modest anti-tumor activity against multiple hematological and solid malignancies in preclinical and phase I/II clinical trials. We investigate whether the antitumor activity of these cellular therapies can be augmented by using a novel method that rapidly affixes tumor-targeting antibodies directly to cell surface proteins. Methods Monoclonal antibodies including rituximab and daratumumab were conjugated to the cell surface proteins using a three step approach. First, we conjugate single-stranded DNAs (ssDNAs) to the therapeutic monoclonal antibodies, as previously described (ref below). Next, we conjugate complementary ssDNAs to surface proteins of cells being used for cellular therapy. Finally, the modified antibodies are attached to the modified cells via hybridization of the complementary DNA strands. Results We demonstrate that multiple anti-neoplastic monoclonal antibodies including rituximab and daratumumab can be conjugated to the surface proteins on a variety of cell including γδ T cells, NK-92 cells, CIK cells, and primary human T cells. Then we evaluated the killing activity of these conjugated cells in vitro, in vivo, and ex vivo . In vitro, Rituximab-armed γδ T cells and NK-92 cells demonstrated increased cytokine production (IFN-γ and granzyme B) and enhanced cytotoxic killing against of multiple human B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma cell lines. Similar enhanced anti-tumor activity was seen with rituximab-armed or daratumumab-armed CIK cells, as well as increased CD107a expression (a marker of cytotoxicity activity) by the antibody-armed CIK cells. Rituximab-armed primary T cells also show enhanced cytotoxic killing against Raji cells, although not as pronounced as autologous rituximab-armed CIK cells. We next evaluated the therapeutic potential of antibody-armed cell therapies in vivo in a disseminated xenograft mouse model using SCID-beige mice. Rituximab-armed γδ T cells exhibited potent anti-lymphoma activity against Raji cells, which lead to improved overall survival; whereas unarmed γδ T cells alone or with rituximab co-infusion demonstrated limited anti-lymphoma activity. We also evaluated the therapeutic activity of antibody-armed cell therapies against a primary lymphoma target ex vivo. Rituximab-arm CIK cells demonstrated enhanced cytolytic activity against primary follicular lymphoma freshly collected from a patient via fine needle aspiration biopsy. Discussion We have demonstrated a novel approach to create tumor-specific cellular immunotherapies without the need for genetic engineering. The antibody to cell conjugation method is straight forward. The modified antibodies can be made and stored until needed. It takes approximately 1 hour to attaching these modified antibodies to the cell surface and is performed in standard aqueous buffers, such as phosphate-buffered saline (PBS). This method is also flexible being able to conjugate multiple different antibodies to the surface proteins of a variety of different cell types. We also see enhanced cell killing across multiple hematological targets using multiple cell populations including γδ T cells, NK-92 cells, CIK cells, and primary human T cells. Overall, our data demonstrate existing monoclonal antibodies can be used to “antibody program” cell therapies for the treatment of hematological malignancies. Ref Hsiao et al Langmuir 2009,25(12), 6985-6991 Disclosures Hsiao: Acepodia, Inc: Employment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
领导范儿的应助被武科大采纳,获得10
刚刚
八爷啦啦啦完成签到,获得积分10
1秒前
1秒前
1秒前
跳跃的静曼完成签到,获得积分20
1秒前
Ruolin完成签到,获得积分10
1秒前
勤劳的潇完成签到,获得积分10
1秒前
1秒前
慕辰完成签到,获得积分20
1秒前
1秒前
2秒前
2秒前
2秒前
2秒前
传奇3的应助被Maestro_S采纳,获得50
2秒前
无花果的应助被lyn123采纳,获得10
2秒前
仁爱的沁发布了新的文献求助50
3秒前
3秒前
shichao发布了新的文献求助10
3秒前
3秒前
C1完成签到,获得积分10
3秒前
3秒前
亚尔驳回了Hello的应助
3秒前
大模型的应助被Rommel采纳,获得10
3秒前
hqf802802完成签到,获得积分10
3秒前
从容盼旋发布了新的文献求助10
4秒前
Lmx发布了新的文献求助10
4秒前
Colin完成签到,获得积分10
4秒前
4秒前
4秒前
巴拉巴拉完成签到,获得积分10
5秒前
xudaniel发布了新的文献求助50
5秒前
5秒前
Criminology34的应助被巴爪鱼采纳,获得10
6秒前
6秒前
6秒前
慕青的应助被嘻嘻采纳,获得10
6秒前
jim完成签到,获得积分10
6秒前
痴情志浩发布了新的文献求助10
6秒前
is_wuwu完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160268
求助须知:如何正确求助?哪些是违规求助? 9555328
关于积分的说明 21727231
捐赠科研通 7750062
什么是DOI,文献DOI怎么找? 3427353
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471707